I'd like to add my appreciation for the dialogue between

New Post Public Reply Private Reply Replies (2) Message Board
sherlock57 Cycl2R #163019
641
I'd like to add my appreciation for the dialogue between twinter and MGK2... Lots of great science there. Answering some fundamental questions with authority... and footnotes. ScoreCarder chips in with his business-as-usual perspective... and knowledge of the FDA process and timelines. Adding in the the perspectives of Plotinus and Misiu just rounds it out all out, with real-world consequences--and patients lives--in the balance. Truly meaningful back-and-forth--which is why I love this board.
Getting back to Cycl2R's original questions about the eventual outcomes of the Clover trial, I'd like to add a few observations from the basket trial that evaluated leronlimab in mCRC. First things first--the dose used for every patient in the 5 patient cohort was 525mg of leronlimab. So not an optimum dose, but not sub-standard. Things like the weight of the individual patient may come into play here... small patients may very well have gotten an optimal dose, while heavier patients could have gotten something less. And if there was liver involvement--liver metastasis--that would mean more CCR5 cells active in the liver, which means more leronlimab would be needed to occupy those receptors. Lung metastasis don't involve as many CCR5 receptors, so the kind of organs that get metastasized have bearing on receptor occupancy. Which is just to say there are a lot of variables at play here... AI tells me: "The site of a patient's colorectal cancer metastasis alters the pharmacokinetics of leronlimab, fundamentally impacting whether a 350mg or a 700mg dose is required."

Out of the five patients in the basket trial, one was given leronlimab as a monotherapy. No chemo. That patient lived 4.2 months. (Rest-in-peace, good soul). Here is an AI-generated response concerning the other four patients:

"Summary Analysis of the 5-Patient Cohort
The collective outcomes show that when Leronlimab was paired with a functional chemotherapy partner (Patients 1, 2, 3, and 4), it achieved a 100% Disease Control Rate (DCR) consisting of 1 CR, 2 PRs, and 1 SD. The only therapeutic failure occurred when the drug was stripped of a chemotherapy partner (Patient 5). This critical insight directly led to the design of the CLOVER trial, ensuring that no patient receives Leronlimab alone and that all participants are paired with an active, resistance-breaking oral partner (TAS-102)".
The median Overall Survival was 15.8 months for the entire cohort... and stayed that way if you subtract the 4.2 months of life at the low end, as well as the 57 months (NED) on the high end. But if you exclude the monotherapy failure, the average--not the median--overall survival was between 23 and 36 months (according to AI). The historical baseline OS of Tas-102 and Avastin is 7.5 months. So, leronlimab and the Folfox chemo backbone basically tripled the average OS. Or better.

I had initially speculated that the inclusion of Avastin may have led to the excellent early ctDNA declines... but that didn't really make sense, upon reflection. Anti-angiogenesis effects--whether from Avastin, or leronlimab, or the combination--would result in loss of blood supply to the tumor, and most likely lead to stable disease/no progression, but not tumor death (ctDNA declines) and shrinkage. MGK2 caught this, and his comments reflected what I gathered from AI--that Tas-102 preferentially interferes with the tumor's DNA replication, killing the tumor more effectively than the Folfox chemo backbone. And leronlimab clearly makes Tas-102 work better, synergistically, and leads to much more ctDNA declines than happened in the basket trial, as evidenced in the early results of the Clover trial (70% declines early, even better later). 

It's not like Avastin didn't have any impact. AI tells me the following: "The addition of Avastin to the fluropyrimidine doublet paired synergystically with leronlimab to control tumor volume. This clinical signal served as the primary proof-of-concept that adding a VEGF inhibitor to a CCR5 blocker enhances treatment efficacy--directly inspiring the triplet-drug architecture of the contemporary Clover trial." Additionally, Bev "physically normalizes the tumor's existing blood vessels so that chemo and immune cells can penetrate the tumor more effectively." (AI).

Cycl2R--Four patients cleared their ctDNA entirely during recent follow-up monitoring in the Clover trial. And 3 out of 4 patients that cleared their ctDNA were from the 350mg group! I'm gonna go out on a limb here... But I'm gonna say that the the 350mg dose of leronlimab, combined with Bev and Taz--is going to beat the SOC and be approvable by the FDA. Like, double or triple or quadruple the SOC. I mean, excluding the one non-chemo patient from the basket trial, you get a 75% ORR. With no ICI. The FDA will start drooling over themselves if we show an ORR of, say, 50% in this MSS mCRC patient population. Leronlimab has proved pretty consistent results in cancer trials. So why not just say it--I expect a 60%+ ORR in the Clover trial (including the 700mg cohort, just to be clear). Consistent/better than the basket trial. I'd lean to even better results, because of the Tas-102 instead of the Folfox/oxaliplatin chemo... but I'm going to be conservative here.

Twinter, MGK2, Scorecarder--Ohm, if you are around--whaddaya think? It's an early call... but a sound call I think, extrapolating from some very significant early results. I think the FDA will confuse things, approve the 350mg dose for mCRC, with Tas-102 and bev, and get in the way of what we all want to see--the LL/ICI combo, and radical Complete Response numbers. What does the FDA do best--slow things down? What I really hope for is the 700mg dose will separate itself in terms of efficacy rather quickly, and increase the PD-L1 numbers as well as achieve some Complete Responses without an ICI... and the FDA will just say "Fuck it, this is a radical breakthrough, even if there is stable disease, just give 'em an ICI and we'll call them cured." But can the FDA go there? Probably... Not!!!

A boy can dream... can't he? But tell me, anyone out there, y'all see an approval for the 350mg dose with Tas and bev? Those are the tea leaves I am reading... Can't predict a timeline, though. But I think the FDA is going to be blown away by the Clover results. And the public--when it gets wind of the EAP TNBC results--is going to go mad. Mad happy! And anyone with cancer, or their loved ones, will demand access. That could get crazy... and quickly. Cytodyn, and especially the FDA--as the gate-keeper--will have some dancing to do. They best be nimble on their feet. It makes me a little queasy that RFKjr will probably bring news of leronlimab to the world... But I don't really care anymore. Great news is great news. Can't wait. 

   

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 81

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 102

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 107

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 35

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading

Top 5 Most Recently Viewed Articles

Duke Robotics Unveils 2025 Insulator Cleaning Initiatives

Updated Category News Views 216

Exciting New Developments at Duke Robotics Duke Robotics Corp. (OTCQB: DUKR) has taken significant strides in the field of advanced robotics and autonomous drone technology. Recently, the company announced its 2025 insulator cleaning operations with the Israel Electric Corporation. This initiative marks an expansion of their innovative IC Drone system during the insulator...

Continue Reading
Understanding Chargebacks: Impact on Merchants and Solutions

Updated Category News Views 232

Unpacking the Chargeback Challenge for Online Businesses Chargebacks stand as a significant concern for many online businesses, especially as recent research reveals a startling statistic: up to 80 percent of chargebacks may be classified as abusive. As the world shifts increasingly towards e-commerce, platforms such as Chargeflow are stepping up to address these issues,...

Continue Reading
Exploration of the Reusable Transport Packaging Landscape 2025-2035

Updated Category News Views 203

The Reusable Transport Packaging Market Overview The global reusable transport packaging market was valued at USD 119.84 billion in recent evaluations and is projected to experience substantial growth, reaching USD 199.74 billion in the near future. This shift is propelled by increasing economic and environmental awareness as businesses look for sustainable packaging...

Continue Reading
Exploring TechnipFMC's Resilience in Offshore Energy Trends

Updated Category News Views 142

Understanding TechnipFMC's Current Position in the Market TechnipFMC plc (NYSE: FTI), a prominent name in the offshore energy sector, has been maneuvering through a challenging landscape in 2024. While the year began slower than anticipated, analysts maintain a positive outlook regarding the company’s future potential. This analysis will explore TechnipFMC's current...

Continue Reading
Cupshe Unveils 'Limitless' Campaign to Empower Women Everywhere

Updated Category News Views 400

Cupshe Introduces the Limitless Campaign The renowned fashion e-tailer Cupshe is excited to announce its new initiative, the Limitless campaign. This campaign is all about celebrating individuality and empowering women across the globe to embrace their true selves. The essence of the campaign focuses on body positivity and inclusivity, shining a spotlight on real women...

Continue Reading